

# Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413



REF: MDOL/CS-SE/2022- 23/011

May 26, 2022

To,

Listing Department

**BSE Ltd**

1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

**Scrip Code: 532637**

Listing Department

**National Stock Exchange of India  
Limited**

“Exchange Plaza”, 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051  
**Symbol: MANGALAM**

**Sub: Outcome of the Board Meeting held on Thursday, May 26, 2022**

**Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD / 4 /2015 dated September 09, 2015**

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Thursday, May 26, 2022 has *inter-alia* transacted the following business:

- The Audited Financial Results (Standalone) for the quarter and Financial Year ended March 31, 2022 pursuant to Regulation 33 of the SEBI LODR Regulations. **(A copy of the said results, notes thereto and Auditor’s Report is annexed hereto and marked as Annexure I.)**
- Appointment of Internal Auditor of the Company for the Financial Year 2022-23. **(Brief profile is attached herewith as Annexure II)**
- Re-Appointment Cost Auditor of the Company for Financial Year 2022-23. **(Brief Profile is attached herewith as Annexure – III)**

We hereby declare that the Auditors have expressed a modified opinion in the Audit Report on the Standalone Audited Financial Results for the quarter and year ended March 31, 2022 and as required we submit Annexure-IV in the prescribed format thereby furnishing the Statement on impact of Audit Qualifications (for Audit Report with modified opinion)

A handwritten signature in black ink, appearing to be the name of a representative of Mangalam Drugs and Organics Ltd.



# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

The meeting of Board of Directors of the Company commenced at 3:00 P.M. and concluded at 06:55 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,  
For **Mangalam Drugs & Organics Limited**

**Govardhan M. Dhoot**  
Chairman & Managing Director  
DIN: 01240086



## MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



## Statement of Audited Financial Results for the Quarter and Year Ended March 31, 2022

Sr.No	Particulars	Quarter Ended			(Rs. In Lacs)	
		31.12.2021		31.03.2021	Year Ended	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		Audited	Unaudited	Audited	Audited	Audited
1	<b>Income from Operations</b>					
	(a) Net Sales and Services from Operations	11,982.99	10,138.12	9,078.70	44,756.13	37,997.73
	(b) Other Operating Income	112.56	49.88	211.38	350.71	472.06
	<b>Total Income from Operations (net) (a+b)</b>	<b>12,095.55</b>	<b>10,188.00</b>	<b>9,290.08</b>	<b>45,106.84</b>	<b>38,469.78</b>
2	<b>Other Income</b>	0.00	0.00	0.00	8.94	0.00
3	<b>Total Income ( 1+2)</b>	<b>12,095.55</b>	<b>10,188.00</b>	<b>9,290.08</b>	<b>45,115.78</b>	<b>38,469.78</b>
4	<b>Expenses</b>					
	(a) Cost of Materials Consumed	7,511.19	7,566.42	5,481.29	33,907.51	25,618.99
	(b) Purchase of Stock in trade	121.58	9.67	0.00	131.24	0.00
	(c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade	766.56	(879.41)	679.82	(3,374.86)	(423.26)
	(d) Employee Benefits Expenses	1,161.56	871.05	846.96	3,725.13	2,987.95
	(e) Depreciation and amortization expenses	268.66	267.17	251.53	1,024.91	917.53
	(f) Other Expenses	1,514.74	1,189.06	1,124.79	5,812.37	4,484.06
	<b>Total Expenses (a to f)</b>	<b>11,344.28</b>	<b>9,023.97</b>	<b>8,384.39</b>	<b>41,226.30</b>	<b>33,585.27</b>
5	<b>Profit / (Loss) before finance cost and exceptional and extraordinary items and tax (3-4)</b>	<b>751.26</b>	<b>1,164.03</b>	<b>905.69</b>	<b>3,889.48</b>	<b>4,884.51</b>
6	Finance costs (net)	253.45	268.68	221.57	1,116.18	932.61
7	<b>Profit / (Loss) before exceptional and extraordinary items and tax(5-6)</b>	<b>497.81</b>	<b>895.35</b>	<b>684.12</b>	<b>2,773.30</b>	<b>3,951.91</b>
8	<b>Exceptional items</b>	0.00	0.00	0.00	0.00	0.00
9	<b>Profit/(Loss) before extraordinary items and tax (7-8)</b>	<b>497.81</b>	<b>895.35</b>	<b>684.12</b>	<b>2,773.30</b>	<b>3,951.91</b>
10	<b>Extraordinary Items</b>	0.00	0.00	0.00	0.00	0.00
11	<b>Profit(+)/Loss (-) before tax(9-10)</b>	<b>497.81</b>	<b>895.35</b>	<b>684.12</b>	<b>2,773.30</b>	<b>3,951.91</b>
12	<b>Tax Expenses</b>					
	Current Tax	130.42	381.27	240.66	880.79	926.78
	Deferred Tax	(301.76)	111.86	228.04	(73.24)	228.04
13	<b>Net Profit(+)/Loss(-) after Tax (11-12)</b>	<b>669.15</b>	<b>402.22</b>	<b>215.42</b>	<b>1,965.75</b>	<b>2,797.09</b>
14	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	6.13	1.55	5.51	11.79	(94.77)
15	<b>Total Comprehensive Income (13+14)</b>	<b>675.28</b>	<b>403.77</b>	<b>220.93</b>	<b>1,977.54</b>	<b>2,702.31</b>
16	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
17	Other Equity				13,473.32	11,495.78
18	<b>Earnings Per Share (EPS) (of Rs 10/-each not annualised):</b>					
	(a) Basic	4.23	2.54	1.36	12.42	17.67
	(b) Diluted	4.23	2.54	1.36	12.42	17.67




## MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Standalone Statement of Assets and Liabilities		Rs. in Lacs	
	As at 31.03.2022 Audited	As at 31.03.2021 Audited	
<b>ASSETS</b>			
<b>A. Non-current Assets</b>			
(a) Property, Plant and Equipment	11503.24	10343.35	
(b) Right to use assets	1158.27	591.10	
(c) Capital Work-In-Progress	17.96	486.92	
(d) Intangible assets	834.73	847.39	
(e) Intangible Assets Under Development	552.90	148.27	
(f) Financial Assets			
(i) Investments	0.43	22.35	
(ii) Other Financial Assets	287.37	246.21	
(g) Other Non-current Assets	241.11	333.21	
<b>Total Non-current Assets (A)</b>	<b>14596.01</b>	<b>13,018.80</b>	
<b>B. Current Assets</b>			
(a) Inventories	11710.55	5858.75	
(b) Financial Assets			
(i) Trade Receivables	4649.01	5431.22	
(ii) Cash and Cash Equivalents	194.69	58.42	
(iii) Bank Balance other than Cash and Cash Equivalents	0.76	0.76	
(iv) Loans	3.61	0.91	
(v) Other Current Asset (Capial Advances)	739.86	122.30	
(c) Other Current Assets (Non Financials)	948.08	1919.73	
<b>Total Current Assets (B)</b>	<b>18246.56</b>	<b>13,392.09</b>	
<b>TOTAL ASSETS (A + B)</b>	<b>32842.57</b>	<b>26,410.89</b>	
<b>EQUITY AND LIABILITIES</b>			
<b>A. Equity</b>			
(a) Equity Share Capital	1582.82	1582.82	
(b) Other Equity	13473.32	11495.78	
<b>Total Equity (A)</b>	<b>15056.14</b>	<b>13,078.60</b>	
<b>B. Non-Current Liability</b>			
(a) Financial Liabilities			
i) Borrowings	2011.35	687.64	
ii) Lease Liabilities	521.40	318.96	
ii) Other Financial Liabilities	0.05	0.05	
(b) Deferred Tax Liabilities (Net)	1349.47	1417.86	
(c) Other Non-Current Liabilities	393.88	0.00	
<b>Total Non-current Liabilities (B)</b>	<b>4276.15</b>	<b>2,424.51</b>	
<b>C. Current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	4709.62	5118.16	
(ii) Lease Liability	387.67	255.31	
(ii) Trade Payables			
Payable to MSME	442.13	551.54	
Other than MSME	5012.58	3787.94	
(iii) Other Financial Liabilities	1160.40	590.58	
(b) Provisions	326.89	40.36	
(c) Other Current Liabilities	1470.99	563.88	
<b>Total Current Liabilities (C)</b>	<b>13510.28</b>	<b>10,907.78</b>	
<b>TOTAL EQUITY AND LIABILITIES (A + B + C)</b>	<b>32842.57</b>	<b>26,410.89</b>	








**Cash Flow Statement For the Period Ended March 31, 2022**

(Rs. In Lacs)

Particulars	For the Period ended		For the Period ended
	March 31, 2022	Audited	March 31, 2021 Audited
<b>A. Cash flow from operating activities</b>			
Net profit before tax and extra ordinary items.	2,773.30		3,951.91
<b>Add / (Less) :</b>			
Depreciation & amortisation	1,024.91		917.53
Interest expenses (net)	1,116.18		932.61
Dividend Income	(0.05)		-
(Gain)/loss on sale of fixed assets	17.36		3.03
Asset Discarded	60.99		4.32
(Gain)/loss on sale of investments	(8.89)		-
Prov of Diminution in value of Investment	10.10		-
Remeasurements of the defined benefit plans	16.64		(133.71)
<b>Operating profit before working capital changes</b>	<b>5,010.53</b>		<b>5,675.69</b>
<b>Adjustment for :</b>			
(Increase)/decrease in short term loans and advances	(2.70)		0.06
(Increase)/decrease in other current assets	354.10		(648.69)
(Increase)/decrease in trade receivables	782.21		(1,360.84)
(Increase)/decrease in inventory	(5,851.80)		625.51
(Increase)/decrease in other non-current assets	50.94		265.82
Increase/(decrease) in trade payables	1,115.22		-1,391.47
Increase/(decrease) in other current liabilities	1,476.93		177.20
Increase/(decrease) in provisions	286.53		(42.20)
Increase/(decrease) in current lease liabilities	132.36		141.77
Increase/(decrease) in non-current liabilities	393.88		-
Increase/(decrease) in non current lease liabilities	202.44		238.91
	<b>(1,059.89)</b>		<b>(1,993.94)</b>
<b>Cash generated from operations</b>	<b>3,950.65</b>		<b>3,681.75</b>
<b>Add / ( Less) :</b>			
Income Tax (Paid)/ Refund	(880.79)		(926.78)
<b>Net cash from operating activities</b>	<b>3,069.86</b>		<b>2,754.97</b>
<b>B. Cash flow from investing activities :</b>			
Purchase of fixed assets including Capital WIP	(2,766.90)		(3,143.61)
Sale of fixed assets	13.57		15.08
Sale/(Purchase) of investments	20.71		-
Divided Income	0.05		-
<b>Net cash from investing activities</b>	<b>(2,732.57)</b>		<b>(3,128.53)</b>
<b>C. Cash flow from financing activities :</b>			
Proceeds/(repayment) of short term borrowing	(408.54)		932.08
Proceeds/(repayment) of long term borrowing	1,323.71		270.36
Interest Paid (net)	(1,116.18)		(932.61)
<b>Net cash used in financing activities</b>	<b>(201.02)</b>		<b>269.83</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>136.27</b>		<b>(103.73)</b>
<b>Cash and cash equivalents - opening balance</b>	<b>58.42</b>		<b>162.16</b>
<b>Cash and cash equivalents - closing balance</b>	<b>194.69</b>		<b>58.42</b>
<b>Details of cash and cash equivalent at the end of the Period / Year</b>			
- Cash in hand	11.61		5.73
- Balance in current & fixed deposit accounts	183.08		52.69
<b>Total</b>	<b>194.69</b>		<b>58.42</b>



**MANGALAM DRUGS AND ORGANICS LIMITED**

**CIN - L24230MH1972PLC116413**

**Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.**



**Notes :**

1	The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
2	The above Audited financial results of the Company for the year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company at their meeting held on May 26, 2022.
3	The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
4	The cost of the leasehold land has been amortised pertains to prior period amounting to Rs.17.58 Lacs are debited to the retained earnings as on March 31st, 2021.
5	The figures for the quarter ended 31st March, 2022 are the balancing figures between the Audited figures in respect of full financial year upto 31st March 2022 / 31st March 2021 and the unaudited published year-to-date figures upto 31st December 2021 / 31st December 2020 being the date of the end of the third quarter of the financial year respectively whichever subjected to limited review.
6	The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.

On behalf of Board of Directors  
For Mangalam Drugs and Organics Limited

Shri Govardhan M.Dhoot  
Chairman and Managing Director  
DIN:01240086



Place:Mumbai  
Date: 26th May, 2022





**Independent Auditor's Report on Quarterly and Year to Date Audited Financial Results of Mangalam Drugs and Organics Limited Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015**

**The Board of Directors,**  
Mangalam Drugs and Organics Limited,  
Rupam Building, 3<sup>rd</sup> Floor,  
239, P.D'Mello Road, Mumbai 400001.

**Report on the audit of the Financial Results**

**Basis of Opinion**

1. We have audited the accompanying statement of quarterly and year to date financial results of Mangalam Drugs and Organics Limited (the 'Company') for the quarter ended on March 31, 2022 (the 'statement') and year to date results for the period April 01, 2021 to March 31, 2022 attached herewith, prepared and submitted by the management of the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the Listing Regulations).
2. In our opinion and to the best of our information and explanations given to us the statement except for the para mentioned below in Basis for opinion :
  - i. is presented in accordance with requirements of the Listing Regulation in this regard; and
  - ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2022 and for the year ended on March 31, 2022
3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
4. **Basis for Qualified Conclusion:**  
Company has capitalised two vehicles amounting to ₹.132 lakhs during the year ended on March 31, 2021 in the names of Individual Directors and has also disclosed the corresponding secured loans availed

from bank as its liabilities, one of the Non-Executive Director had resigned during the year ended on March 31, 2021. Ownership of the vehicles are not yet transferred in the name of the Company, hence the assets of the Company are overstated to the extent of ₹108.80 lakhs net of Depreciation, liabilities are overstated to the extent of ₹.67.92 lakhs.

Since the ownership of the vehicles are not in the name of the Company, the expenses are overstated for the quarter ended March 31, 2022 by ₹ 05.30 lakhs and for the year ended on March 31, 2022 by ₹ 22.01 lakhs to that extent Profit for the Quarter and year ended has been understated.

We have been informed that the Company has taken possession of these Vehicles as on March 29, 2022.

**5. Qualified Conclusion:**

Based on our review conducted as above, except matter as specified in para 4 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**6. Management's responsibilities for the stand alone financial statement**


The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

7. In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

**8. Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted





in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **9. Other Matter**

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published




unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

10. The financial statements of the Company for the quarter and year ended March 31, 2021 prepared in accordance with Companies (Accounting Standards) Rules, 2006, were audited by the another firm of chartered accountants under the Companies Act, 2013 who, vide their report dated May 20, 2021 expressed an qualified opinion on those financial statements.

Our conclusion is unqualified in respect of matter related with para 9 and 10 as stated above

**For V. S. SOMANI & CO.,**  
Chartered Accountants  
Firm Registration No.:11,7589



.s man

**CA. VIDYADHAR SOMANI**  
Proprietor  
Membership No: 102664  
UDIN No. 22102664AJQXTR8694

Place: Mumbai  
Date: May 26,2022

## ANNEXURE IV

### Statement on Impact of Audit Qualifications (for audit report with modified opinion) submitted along-with Annual Financial Results - (Standalone)

(Rupees in Lakhs)

Statement on Impact of Audit Qualifications for the Financial Year ended March 31, 2022				
[See Regulation 33 / 52 of the SEBI (LODR) (Amendment) Regulations, 2016]				
I.	Sl. No.	Particulars	Audited Figures (as reported before adjusting for qualifications)	Adjusted Figures (audited figures after adjusting for qualifications)
	1.	Turnover / Total income	45115.78	45115.78
	2.	Total Expenditure (Excluding Tax Expenses)	42342.48	42320.47
	3.	Net Profit/(Loss) (After tax)	1965.75	1943.74
	4.	Earnings Per Share	12.42	12.28
	5.	Total Assets	32842.57	32733.77
	6.	Total Liabilities	32842.57	32774.65
	7.	Net Worth	15056.14	15034.13
	8.	Any other financial item(s) (as felt appropriate by the management)	-	-

**Audit Qualification (each audit qualification separately):**

a. **Details of Audit Qualification:** The Company has capitalised two vehicles amounting to Rs. 132 lakhs during the year ended on March 31, 2021 in the names of Individual Directors and has also disclosed the corresponding secured loans availed from bank as its liabilities, one of the Non-Executive Director had resigned during the year ended on March 31, 2021. Ownership of the vehicles are not yet transferred in the name of the Company, hence the assets of the Company are overstated to the extent of Rs. 108.80 lakhs net of Depreciation, liabilities are overstated to the extent of Rs. 67.92 lakhs. Since the ownership of the vehicles are not in the name of the Company, the expenses are overstated for the quarter ended March 31, 2022 by Rs. 05.30 lakhs and for the year ended on March 31, 2022 by Rs. 22.01 lakhs to that extent Profit for the Quarter and year ended has been understated.

b. **Type of Audit Qualification:** Qualified Opinion.

c. **Frequency of qualification:** Second time





d. **For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views:**  
The Company had acquired two vehicles for the purpose of business in the previous year and registered under Motor Vehicle Act 1988 in the name of the Directors. The purchase of the vehicles are as per the contractual obligation of the Company with the Directors, hence it has been capitalized in the books of account. The payments are made by the Company being the beneficial owner of the Asset, hence the depreciation and interest on borrowings has been charged by the Company in its books of account. The Company has already taken the possession of the Vehicles and are being used for the purpose of business by the Company.

# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

e. For Audit Qualification(s) where the impact is not quantified by the auditor:	
	(i) Management's estimation on the impact of audit qualification: NA
	(ii) If management is unable to estimate the impact, reasons for the same: NA
	(iii) Auditors' Comments on (i) or (ii) above: NA
III.	<p>Signatories</p> <ul style="list-style-type: none"><li>• Managing Director </li><li>• CFO </li><li>• Audit Committee Chairman <i>Scj-</i></li><li>• Statutory Auditor  </li></ul> <p>Place: Mumbai Date: 26.05.2022</p>



# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

## Annexure II

### **Brief Profile of Internal Auditor of the Company for the Financial Year 2022-23**

We further submit the following details as required under Regulation 30 of the SEBI (LODR), Regulation, 2015 read with Circular No, CIR / CFD / CMD / 4 / 2015 dated 9th September, 2015.

<b>Name of the Firm</b>	Bipin Zavar & Associates, Chartered Accountants
<b>Date of Appointment</b>	26.05.2022
<b>Financial Year</b>	2022-23
<b>Term of Appointment</b>	As per Appointment Letter.
<b>Reason of Change/Appointment</b>	In accordance with the provisions of Section 138 of Companies Act, 2013, the Company has appointed Internal Auditor for conducting the Internal Audit of the Company for Financial Year 2022-23.
<b>Brief Profile</b>	M/s Bipin Zavar & Associates is a firm of experienced Chartered Accountants providing specialized services in the area of Audit & Assurance, direct and Indirect Tax, Business Advisory, Accounting and Regulatory compliances providing Specialized Quality Services with client needs and servicing at the center.



# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

## Annexure III

### **Brief Profile of Cost Auditor of the Company for the Financial Year 2022-23**

<b>Name of the Firm</b>	Rampurawala Mohammed A & Co
<b>Date of Appointment</b>	26.05.2022
<b>Financial Year</b>	2022-23
<b>Term of Appointment</b>	As per Appointment Letter.
<b>Reason of Change/Appointment</b>	In accordance with the provisions of Section 148 of Companies Act, 2013, the Company has appointed Cost Auditor for conducting the Cost Audit of the Company for Financial Year 2022-23.
<b>Brief Profile</b>	Enduring with 12 years of experience M/s Rampurawala Mohammed A & Co is one of the leading Cost and Management Accounting Firm. They provide Cost Accounting Services, Cost Audit Services, Management Services, Financial planning Consultancy, etc.

A handwritten signature in black ink, appearing to be 'M. A. R.', is written on the page.

